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Abstract
Dimethyl sulfoxide (DMSO) is widely used as a solvent or vehicle for biological studies, and for treatment of specific
disorders, including traumatic brain injury and several forms of amyloidosis. As Alzheimer’s disease (AD) brains are
characterized by deposits of b-amyloid peptides, it has been suggested that DMSO could be used as a treatment for this
devastating disease. AD brains are also characterized by aggregates of hyperphosphorylated tau protein, but the effect of
DMSO on tau phosphorylation is unknown. We thus investigated the impact of DMSO on tau phosphorylation in vitro and in
vivo. One hour following intraperitoneal administration of 1 or 2 ml/kg DMSO in mice, no change was observed in tau
phosphorylation. However, at 4 ml/kg, tau was hyperphosphorylated at AT8 (Ser
202/Thr
205), PHF-1 (Ser
396/Ser
404) and AT180
(Thr
231) epitopes. At this dose, we also noticed that the animals were hypothermic. When the mice were maintained
normothermic, the effect of 4 ml/kg DMSO on tau hyperphosphorylation was prevented. On the other hand, in SH-SY5Y
cells, 0.1% DMSO induced tau hyperphosphorylation at AT8 and AT180 phosphoepitopes in normothermic conditions.
Globally, these findings demonstrate that DMSO can induce tau hyperphosphorylation indirectly via hypothermia in vivo,
and directly in vitro. These data should caution researchers working with DMSO as it can induce artifactual results both in
vivo and in vitro.
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Introduction
Dimethyl sulfoxide (DMSO), a polar aprotic solvent that dissolves
a great variety of both polar and nonpolar substances, is miscible in
many organic solvents as well as water and has been used for diverse
laboratory and clinical purposes [1,2]. DMSO can also be used as an
additive, which improves absorbability of poorly water-soluble drugs
without affecting the membrane integrity [3]. The compound has
widespread pharmacological and research applications [2]. For
instance, it is used as a drug carrier to cells [4] and as a cryoprotector
[5,6]. An example of the use of DMSO as a drug carrier in the
Alzheimer’s disease (AD) field is the work on selective inhibitors of
Glycogen Synthase Kinase-3 b (GSK-3b) in vivo and in vivo [7–10].
In clinical practice, DMSO can be used for treatment of specific
disorders, including several forms of amyloidosis [2], but also in
cardiac, or central nervous system damage such as traumatic brain
injury (TBI) [11]. As AD brains are characterized by extracellular
deposits of b-amyloid peptides, it has been suggested that DMSO
could be used as a treatment for this devastating disease [2,12].
AD and TBI brains are also characterized by intracellular
aggregates of hyperphosphorylated tau protein, but the effect of
DMSO on tau phosphorylation is unknown. Since DMSO could
be a drug candidate in AD and TBI and since DMSO is widely
used in the laboratory, notably as drug carrier for tau kinases
inhibitors, we investigated the effect of DMSO on the phosphor-
ylation of tau in vivo and in vitro.
One hour following intraperitoneal administration of 4 ml/kg
DMSO in mice, but not at lower doses, tau was hyperpho-
sphorylated at AT8 (Ser
202/Thr
205), PHF-1 (Ser
396/Ser
404) and
AT180 (Thr
231) epitopes. However, the mice were hypothermic at
this dose, and maintaining them normothermic prevented the
effect of DMSO. In SH-SY5Y cells, 0.1% DMSO induced tau
hyperphosphorylation at AT8 and AT180 phosphoepitopes in
normothermic conditions.
Globally, these findings demonstrate that DMSO can induce
tau hyperphosphorylation indirectly via hypothermia in vivo, and
directly in vitro.
Results
Tau Phosphorylation 1 h following the Administration of
DMSO at 0, 1, 2, and 4 ml/kg i.p
We first examined whether DMSO i.p. doses lead to a change
in tau phosphorylation in mice. For this purpose, western blot
analyses with antibodies targeting key tau phosphoepitopes were
used in hippocampus homogenate from mouse injected with either
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e400200, 1, 2 or 4 ml/kg DMSO i.p. These doses are well below the
reported LD50 of 13.4–15.5 g/kg (12.2–14.1 ml/kg) in mice
[13,14], and indeed, we did not detect cell death or induction of
apoptosis as determined by examining Poly (ADP-ribose) poly-
merase cleavage or caspase 3 activation (data not shown). AT8,
PHF-1 and AT180 antibodies are specific to tau phosphorylated at
Ser
202/Thr
205, Ser
396/Ser
404, and Thr
231/Ser
235, respectively,
which are known to be highly phosphorylated during tau
pathogenesis [15–19]. One hour following administration, DMSO
produced a significant increase in hippocampal tau phosphoryla-
tion (expressed as a ratio of phosphotau to total tau) at the AT8
(+289%), PHF-1 (+42%), and AT180 (+76%) phosphoepitopes in
mice injected with an i.p. dose of 4 ml/kg, when compared to the
control group (0 ml/kg) (Fig. 1A-C). One or 2 ml/kg did not lead
to change in tau phosphorylation (Fig. 1A-C). A slight increase in
total tau in the 4 ml/kg group was also observed (+18%)
compared to the control (0 ml/kg) (Fig. 1D). We have previously
observed slight increases in total tau following hypothermia
induced by anesthesia [20] or diabetes [21], but we do not know
the cause of this phenomenon at this time. Nevertheless, our
results demonstrate that DMSO can induce tau hyperphosphor-
ylation at multiple epitopes in the mouse brain.
Immunohistochemistry also Reveals a Tau
Hyperphosphorylation Effect of DMSO
Immunostaining of hippocampal sagittal sections of mice
revealed a robust hyperphosphorylation of tau at the AT8 epitope
1 h after injection of the highest dose of DMSO (Fig. 2B, D, F)
compared to controls (Fig. 2A, C, E). The immunohistochemistry
results are in accordance with our Western blot data (Fig. 1A). In
AD, the hyperphosphorylation of tau occurs first in neurites and is
then followed by somatodendritic relocalization [22]. Here, no
obvious somatodendritic relocalization was observed in our
immunostainings. These results confirm our Western blot analysis
and show that DMSO did not induce a shift of tau from the axons
to the soma.
Impact of DMSO on Tau Kinases
We next attempted to clarify the mechanism of DMSO-induced
hyperphosphorylation by examining the activation of specific tau
kinases commonly involved in the regulation of tau phosphory-
Figure 1. Tau phosphorylation in mouse hippocampal tissue 1 h following the administration of DMSO at 0, 1, 2, and 4 ml/kg i.p.
Hippocampal protein extracts were separated by SDS-PAGE and levels of tau phosphorylation were determined using antibodies directed at the (A)
AT8 (pSer
202/pThr
205), (B) PHF-1 (pSer
396/pSer
404), (C) AT180 (pThr
231/pSer
235) phophoepitopes, or (D) total Tau. For each phosphoepitope, relative
immunoreactive band intensities are expressed as a ratio to total tau and are displayed as a percentage of control (0 ml/kg of DMSO). For each
condition, 2 representative data are displayed with controls (0 ml/kg; n =5), 1 ml/kg (n =5), 2 ml/kg (n =5) and 4 ml/kg (n =5). Data are expressed
as mean 6 SD. *, **, *** denote p,0.05, p,0.01 and p,0.001 versus control, respectively; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0040020.g001
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the activation patterns of seven kinases with specific antibodies in
the same hippocampal tissues previously used for tau phosphor-
ylation analysis. A dose of 4 ml/kg of DMSO significantly
increased phospho-GSK-3b (Ser9, inhibitory phosphorylation)
levels (+58%; Fig. 3E), but pERK/ERK ratio (Fig. 3A), pJNK/
JNK ratio (Fig. 3C), pCaMKII/CaMKII ratio (Fig. 3G), phospho-
P38 MAPK/P38 MAPK ratio (Fig. 3I), CDK5 (Fig. 3K) and p35
(Fig. 3L) did not change compared to controls (0 ml/kg). Our
results fail to explain the increase in tau phosphorylation in terms
of kinases activation.
Effect of DMSO on Tau Phosphatases
As no changes in kinases could explain the hyperphosphoryla-
tion of tau AT8, PHF-1 and AT180 phosphoepitopes, we
examined next the levels of the catalytic subunits of PP1, PP2B,
PP2A, and PP5 1 h after DMSO administration. Tau can be
dephosphorylated by PP1, PP2A, PP2B, and PP5, but PP2A shows
a much stronger ability to dephosphorylate tau [23,24]. Immu-
noblot analysis revealed a slight decrease of the regulatory subunit
A of PP2A 1 h after administration of 2 (-15%) or 4 ml/kg (-12%)
of DMSO (Fig. 4B). As PP2A A is decreased at both 2 and 4 ml/
kg, it is unlikely to be the cause of tau hyperphosphorylation at the
higher dose. There was no change in PP1, PP2A-Ba and PP2A-Bb
subunits, demethylated PP2A-C/PP2A-C ratio, PP2B, or PP5
levels was observed following 1, 2, or 4 ml/kg of DMSO i.p.,
compared to controls (0 ml/kg) (Fig. 4A, C-H). Here again, there
was no clear correlation between tau hyperphosphorylation and
changes in phosphatases levels.
Four ml/kg DMSO Induces a Transient Hypothermia After
1 h in Mouse
Since tau hyperphosphorylation may be the consequence of
hypothermia [20,25–31], we examined whether DMSO i.p. doses
led to a change in body temperature in mouse. Four ml/kg of i.p.
DMSO decreased the mouse rectal temperature to 34.660.3uC
versus 37.060.2uC 30 min after administration (p,0.001),
34.760.4 versus 37.360.2uC 60 min after administration
(p,0.001), and 34.760.8uC versus 37.460.2uC 120 min after
administration (p,0.001) from the control group (0 ml/kg) (Fig. 5).
However, i.p. doses of 1 and 2 ml/kg of DMSO did not
significantly change the body temperature of mice at any time
point (Fig. 5). Thus, tau hyperphosphorylation after injection of
DMSO seems to be associated with hypothermia at 4 ml/kg.
Normothermia Prevents DMSO-induced Tau
Hyperphosphorylation
To demonstrate a causative effect of hypothermia on tau
hyperphosphorylation at 4 ml/kg DMSO, the body temperature
of a group of DMSO-injected mice was maintained at ,37uC
using a ventilated incubator. In the hypothermic group, 1 hr
following administration, 4 ml/kg DMSO produced a significant
increase in hippocampal tau phosphorylation at the AT8 (+168%),
PHF-1 (+49%), and AT180 (+84%) phosphoepitopes in mice,
when compared to the control group (0 ml/kg; Fig. 6A-C), in
accordance with our dose-response analysis (Fig. 1). However, tau
hyperphosphorylation at the AT8, PHF-1 and AT180 epitopes
was prevented in the normothermic group (Fig. 6A-C). Levels of
total tau remained unchanged in hypothermic and in normother-
mic conditions compared to controls (0 ml/kg; Fig. 6D). There-
fore, hypothermia seems to be the indirect cause of the effect of
4 ml/kg DMSO on tau hyperphosphorylation at multiple epitopes
in the mouse brain.
DMSO Induces Tau Hyperphosphorylation in SH-SY5Y
Cells
As we have seen above, one of the effects of DMSO is indirect,
via hypothermia at a 4 ml/kg dose. But we also wanted to explore
the effects of direct application of DMSO on neuronal-like cells.
Thus, we next determined the effect of DMSO on tau
phosphorylation at the AT8, AT180 and PHF-1 phosphoepitopes
using SH-SY5Y human neuroblastoma cells stably transfected to
express human tau with 3 microtubule binding domains (htau
Figure 2. Regional anatomical localization of phosphorylated tau protein in DMSO treated mice at 5X (A-B, G-H, M-N), 20X (C-D, I-J,
O-P) and 40X magnification (E-F, K-L, Q-R). Fluorescent photomicrographs of hippocampal sagittal sections are shown with AT8 (Red, A-F), Total
Tau (Green, G-L), or merged with DAPI (M-R), for the following groups: control (A, C, E, G, I, K, M, O, Q) or DMSO-treated mice (B, D, F, H, J, L, N, P, R).
doi:10.1371/journal.pone.0040020.g002
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because it is roughly equivalent to the concentration of DMSO in
the brain after 1 h following injection of 4 ml/kg i.p. [32]. One-
hour exposure to 0.1% DMSO increased tau phosphorylation at
AT8 (+325%) and AT180 (+400%) phosphoepitopes (Fig. 7A, C).
Phosphoepitope PHF-1 and total tau remained unchanged after
0.1% DMSO exposure in htau SH-SY5Y cells (Fig. 7B, D). These
results demonstrate that application of DMSO onto neuronal cells
can lead to direct tau hyperphosphorylation.
Discussion
The work presented here provides novel evidence that DMSO,
which is extensively used in laboratory, increases tau phosphor-
ylation indirectly via hypothermia in vivo, and directly in vitro.
We first examined the effect of increasing doses of DMSO from
1 to 4 ml/kg on tau phosphorylation in mice. In vivo, DMSO is
used at a wide range of concentrations. For example, doses of
0.1 ml/kg [33], 1 ml/kg [34], 2 ml/kg [35,36], and 4 ml/kg [37]
or higher [38] have been utilized. Here, we observed an increase
in tau phosphorylation at all the examined epitopes (AT8, AT180,
PHF-1), only at 4 ml/kg. All these tau epitopes are highly
phosphorylated in AD [15–19], and have been associated with
paired helical filament and neurofibrillary tangles formation [39].
Therefore, it appears that DMSO exposure can result in an
increase in tau phosphorylation at epitopes that are critical for the
development of tau pathology.
We also noticed that the mice were hypothermic following a
4 ml/kg dose. DMSO has previously been documented to induce
hypothermia in rats and mice [32,40] but the minimal dose for this
effect was not reported. Here we demonstrate that doses of 1 or
2 ml/kg did not induce hypothermia, but 4 ml/kg and above
(6 ml/kg, data not shown) did in a 30 to 120 min timeframe
following i.p. administration. We have previously demonstrated
that tau phosphorylation in vitro or in vivo is exquisitely sensitive to
hypothermia, and that hypothermia induced by a variety of drugs
such as anesthetics or by alteration of metabolism will always result
in hyperphosphorylation at multiple epitopes by direct inhibition
of PP2A [20,25–28]. Here, DMSO at 4 ml/kg induced hypo-
thermia and resulted in an extensive tau hyperphosphorylation
Figure 3. Effect of DMSO on tau kinases in mouse hippocampal tissue 1 h following the administration of DMSO (4 ml/kg i.p.).
Hippocampal protein extracts were separated by SDS-PAGE and levels of kinases were determined using antibodies directed at activated or total
kinases as follow: (A) phospho-ERK/total ERK ratio, (b) total ERK, (C) phospho-JNK/total JNK ratio, (D) total JNK, (E) GSK-3b phospho-S9/total GSK-3b
ratio, (F) total GSK-3b, (G) phospho-CaMKII/total CaMKII ratio, (H) total CaMKII, (I) phospho-P38/total P38 ratio, (J) total P38, (K) CDK5, and (L) p35.
Relative immunoreactive band intensities are expressed as a percent of control (0 ml/kg of DMSO) and are displayed for each epitope. For each
condition, 2 representative data are displayed with controls (0 ml/kg; n =5), 1 ml/kg (n =5), 2 ml/kg (n =5) and 4 ml/kg (n =5). Data are expressed
as mean 6 SD. *, **, *** denote p,0.05, p,0.01, p,0.001 versus control; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0040020.g003
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results demonstrate that DMSO-induced tau hyperphosphoryla-
tion is indirect and due to hypothermia in vivo.
We also observed an increase in GSK-3b Ser9 phosphorylation
at 4 ml/kg DMSO. This enhanced GSK-3b Ser9 phosphorylation
is seen in different animal models undergoing hypothermia
[20,21,26,27,31] and is probably mediated through the inhibition
of phosphatases such as PP2A at low temperatures. Indeed,
inhibition of PP2A by okadaic acid has been demonstrated to
increase Ser9 phosphorylation [41,42].
DMSO is widely used in vitro at 0.1% or less [9,43,44]. Some
studies also reported the utilization of DMSO at 1% in vitro [45].
Exposure of 0.1% DMSO in Tau-SH-SY5Y human neuroblas-
toma cells increased tau phosphorylation at AT8 and AT180
phosphoepitopes, but not at PHF-1, demonstrating that DMSO
can directly increase tau phosphorylation, albeit at specific
epitopes. DMSO readily crosses the blood-brain barrier [46], so
the lack of direct effect of DMSO in vivo compared to in vitro is
probably not a problem of neurons being not exposed to DMSO.
There are several possible explanations for this discrepancy. One
is that tau in the mouse brain is mainly axonal, while it is cytosolic
in the cells, thus being exposed to different populations of kinases
and phosphatases. Another explanation could be that neurons in
situ require higher doses of DMSO than SH-SY5Y cells to display
tau hyperphosphorylation, as 0.1% of DMSO in vitro is roughly
equivalent to the brain concentration of DMSO after an i.p.
injection of a 4 ml/kg dose [32]. This hypothesis could be tested
by injecting DMSO at higher doses in mice and maintain them
normothermic. However, our animal ethic committee has not
allowed us to utilize DMSO above 4 ml/kg i.p. in mice, except to
obtain pilot data at the beginning of the study.
Globally, our data demonstrate that DMSO can induce in vitro
direct, and in vivo indirect (via hypothermia) hyperphosphorylation
of tau. Our results should caution researchers working with
DMSO and examining tau protein both in vitro and in vivo. When
working with animals, we recommend to always check their
temperature, and to maintain them normothermic when using
doses of 4 ml/kg or above.
Materials and Methods
Animals
The study and the use of animals were approved by the Comite ´
de Protection des Animaux du CHUL and all procedures were
performed according to the guidelines of the Canadian Council on
Animal Care. Four month-old C57/129 mice of either sex were
utilized in this study. The mice were housed in a temperature-
controlled room at 22uC and were kept on a 12 h/12 h light/dark
cycle. All animals had access to food and water ad libitum.
DMSO Exposure
Unless otherwise noted, reagents were obtained from Sigma-
Aldrich (St. Louis, MO). Animals were exposed to 0, 1, 2 or 4 ml/
kg of 99.7% pure DMSO (#BP231, Fisher Scientific, Ottawa,
ON, Canada) via intraperitoneal (i.p.) injections from a 10%
solution of DMSO in 0.9% NaCl freshly prepared. An equal
Figure 4. Effect of DMSO on tau phosphatases in mouse hippocampal tissue 1 h following the administration of DMSO (4 ml/kg
i.p.). Hippocampal protein extracts were separated by SDS-PAGE and levels of phosphatases were determined using antibodies directed at activated
or total kinases as follows: (A) PP1, (B) PP2A regulatory subunit A, (C) PP2A-Ba subunit, (D) PP2A-Bb subunit, (E) demethylated PP2A catalytic C
subunit/total PP2A catalytic C subunit ratio, (F) total PP2A catalytic C subunit, (G) PP2B, and (H) PP5. Relative immunoreactive band intensities are
expressed as a percent of control (0 ml/kg) and are displayed for each epitope. For each condition, 2 representative data are displayed with controls
(0 ml/kg; n =5), 1 ml/kg (n =5), 2 ml/kg (n =5) and 4 ml/kg (n =5). Data are expressed as mean 6 SD. *, ** denote p,0.05, p,0.01 versus control,
respectively; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0040020.g004
Figure 5. Body temperature follow-up following 0 (n =4–22), 1 (n =4–10), 2 (n =4–10) and 4 ml/kg (n =4–28) of DMSO i.p
administration. Data are expressed as mean 6 SEM. **, *** denote p,0.01, p,0.001 versus control (0 ml/kg of DMSO); ANOVA with Newman-Keuls
post hoc for each time point.
doi:10.1371/journal.pone.0040020.g005
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conditions, mice were kept at room temperature. In normothermic
conditions, the body temperature was maintained at ,37uCi na
ventilated incubator. Rectal temperatures were monitored using
an electronic thermometer probe (Thermalert TH-5, Physitemp,
Clifton, NJ).
Preparation of Mouse Brain Protein Extracts
Following DMSO exposure, mice were killed by decapitation
without anesthesia, since anesthesia increases hypothermia-induced
tau phosphorylation [26], 1 h following vehicle or DMSO admin-
istration. Brains were immediately removed and dissected on ice
within one minute. The tissues were immediately frozen on dry ice
a n ds t o r e da t- 8 0 uC. Hippocampal protein extracts were prepared by
sonicating (MP Biomedicals, Solon, OH) the frozen hippocampi in
10X vol/wt RIPA buffer containing 50 mM Tris-HCl, pH 7.4,
1 mM EDTA, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-
40, phosphatase inhibitors (1 mM sodium vanadate and 1 mM
sodium fluoride), and protease inhibitors (Proteases Inhibitors
Cocktail P8340, Sigma-Aldrich, 10 ml/ml, and 1 mM PMSF). The
samples were then centrifuged at 20,000 g for 20 min at 4uC, and the
supernatants were recuperated and kept stored at -80uC.
Cell Culture Studies and Cell Lysate Protein Extract
Preparation
DMSO-induced tau phosphorylation was also examined using
SH-SY5Y human neuroblastoma cells stably transfected to
constitutively express human tau with 3 microtubule binding
domains [39,47–49]. These 3R tau SH-SY5Y cells were a kind gift
of Dr. Luc Bue ´e. The cells were maintained in DMEM with 10%
fetal calf serum (Hyclone, Thermo Fisher Scientific, Waltham,
MA, USA), 2 mM L-glutamine (Invitrogen, Carlsbad, CA) in a
5% CO2 humidified incubator at 37uC. In preparation for DMSO
or vehicle exposure, the cells were transferred into dishes and used
at approximately 70% confluency. On the day of the experiment,
the growth medium was removed by aspiration, and each well was
washed 2 times with 1 mL of fresh DMEM containing no
additives. The cells were incubated with 0.1% DMSO or 1X PBS
for the controls for 1 h at 37uC. Following the exposure, the
DMSO or control solutions were removed by aspiration, and each
plate was rinsed 2 times with 1 mL of PBS. The cells were
harvested in ice-cold RIPA buffer containing phosphatase and
protease inhibitors (same inhibitors as mouse brain protein extracts
in previous section). The lysate was then centrifuged at 20,000 g
for 20 min at 4uC, and the supernatant was collected and analyzed
Figure 6. Tau phosphorylation in mouse hippocampal tissue 1 h following the administration of DMSO (4 ml/kg i.p.) under
hypothermic (Hypo) and normothermic (Normo) conditions. Hippocampal protein extracts were separated by SDS-PAGE and levels of tau
phosphorylation were determined using antibodies directed at the (A) AT8 (pSer
202/pThr
205), (B) PHF-1 (pSer
396/pSer
404), (C) AT180 (pThr
231/pSer
235)
phophoepitopes, or (D) total Tau. For each phosphoepitope, relative immunoreactive band intensities are expressed as a ratio to total tau and are
displayed as a percentage of control (0 ml/kg of DMSO). For each condition, 2 representative data are displayed with controls (0 ml/kg; n =5), 4 ml/
kg DMSO in hypothermic conditions (n =5), and 4 ml/kg DMSO in normothermic conditions (n =6). Data are expressed as mean 6 SD. **, *** denote
p,0.01, p,0.001 versus control, respectively; ANOVA with Newman-Keuls post hoc test.
doi:10.1371/journal.pone.0040020.g006
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(Thermo Fisher scientific). Samples were then stored at 280uC
until immunoblotting analyses.
Western Blot Analysis
Samples were processed as previously described [25], with
modifications. Briefly, proteins were mixed with NuPAGEH LDS
Sample Buffer (Invitrogen) containing 5% 2-mercaptoethanol and
boiled for 10 minutes. The expressions of phosphorylated tau, total
tau as well as tau kinases and phosphatases were determined using
SDS-polyacrylamide gel electrophoresis (PAGE) coupled with
Western blot analysis. Brain homogenate or cell lysate extracts
containing 20 mg protein were separated on a SDS-10%
polyacrylamide gel and then transferred onto nitrocellulose
membranes (Amersham Biosciences, Pittsburgh, PA). Non-specific
binding sites were blocked with 5% nonfat dry milk in Tris-
buffered saline containing 0.1% Tween 20 for 1 h at room
temperature at then were incubated overnight at 4uC with
antibodies directed against either total tau, phosphorylated tau,
specific tau kinase or phosphatase. The following day, membranes
were washed 3 times and then incubated for 1 h at room
temperature with a horseradish peroxidase-linked secondary anti-
mouse or anti-rabbit antibody (Cell Signaling Technology,
Danvers, MA, 1:5,000 dilution), and the immunoreactive band
signal intensity was visualized by enhanced chemiluminescence
(ECL Plus, GE Healthcare Biosciences, Piscataway, NJ). The
immunoreactive bands were scanned using Fujifilm LAS 4000
imaging system (GE Healthcare Biosciences, Piscataway, NJ) and
densitometric analysis was performed on these scans with
ImageGauge analysis software (Fujifilm USA, Valhalla, NY).
Antibodies
Monoclonal antibodies were utilized in the study that were
directed at tau phosphorylated at the following epitopes: AT8
(pSer
202/pThr
205, MN1020, [16] 1:1000 dilution, Thermo Scien-
tific, Rockford, IL), AT180 (pThr
231, 1:1000 dilution, Thermo
Scientific), PHF-1 (pSer
396/Ser
404 [50], 1:1000). Total tau was
detected using Tau A0024 (polyclonal, 1:1000, Dako Cytomation,
Carpinteria, CA, USA) which detects all 6 six isoforms of tau. The
PHF-1 antibody was a generous gift from Dr. Peter Davies (Albert
Einstein University, New York, NY).
Changes in tau kinases were examined using GSK-3b (1:1000,
BD Transduction Lab, Franklin Lakes, NJ), and the following
antibodies purchased from Cell Signaling: phospho-GSK-3b (Ser
9,
1:1000), SAPK/JNK (1:1000), phospho-SAPK-JNK (Thr
183/
Tyr
185, 1:1000), p44/42 MAPK (Erk 1/2, 1:1000), phospho
p44/42 MAPK (Erk 1/2, Thr202/Tyr204, 1:1000). Cyclin
dependent kinase 5 (Cdk5, C-8, 1:1000), p35 (C-19, 1:1000) and
phospho-Ca
2+/calmodulin-dependent protein kinases II (CAM-
KII, Thr
286, 1:1000) and total CamKII (1:1000) were purchased
from Santa Cruz Biotechnology, Santa Cruz, CA, and p38 MAP
Kinase (1:1000) and Phospho-p38 MAPK (Thr
180/Tyr
182, 1:1000)
were purchased from New England BioLabs (Ipswich, MA).
Changes in tau phosphatases were examined using PP1 catalytic
subunit (E-9, 1:1000, Santa Cruz), PP2A-A subunit (1:1000, Cell
Signaling), PP2A-Ba subunit (PPP2R2A (2G9), 1:1000, Cell
Signaling), PP2A-Bb subunit (PPP2R2B, 1:1000, Bethyl Labora-
tories, Montgomery, TX), PP2A-C subunit (1:1000, Cell Signal-
ing), demethylated PP2A-C subunit (1:1000, Millipore, Billerica,
MA), pan-calcineurin A (PP2B, 1:1000, Cell Signaling), and PP5
(1:1000, Cell Signaling).
Immunofluorescence
Tissue fixation was done according to the ‘‘cold Bouin’s
method’’ [27]. Briefly, animals were killed by decapitation without
anesthesia to avoid tau hyperphosphorylation [26], the brain was
quickly removed and immersed in ice-cold Bouin’s solution
(saturated picric acid, formalin, acetic acid at 15:5:1, v/v/v) for
24 hr and embedded in paraffin blocks. Eight to ten micrometer
thick sections were processed for immunohistochemical analyses.
Deparaffinized and hydrated sections were incubated in Target
Retrieval Solution (Dako, Carpinteria, CA) at 70uC for 25 min for
enhancement of the immunoreactivity and then incubated in 7%
normal goat serum, 0.2% triton, 1% BSA in PBS 0.1 M at RT for
1 hr. The specimens were incubated with the primary antibodies
diluted in PBS 0.1 M containing 0.04% triton overnight at 4uC.
The following antibodies were used: AT8 (monoclonal, 1:200
dilution, Pierce Biotechnology, Rockford, IL) and Tau A0024
(polyclonal, 1:500, Dako Cytomation, Carpinteria, CA, USA).
Bound antibodies were visualized with Alexa Fluor 568 conjugated
anti-mouse IgGc1 (1:500 dilution) or Alexa Fluor 488 conjugated
anti-rabbit IgG (1:1000 dilution) (Molecular Probes, Eugene, OR).
Slices were mounted with a Vectashield Hard Set Mounting
Figure 7. Effect of DMSO on tau phosphorylation in 3R human
tau transfected SH-SY5Y cells following 1 h exposure. Cell lysate
protein extracts were separated by SDS-PAGE and levels of tau
phosphorylation were determined using antibodies directed at the (A)
AT8, (B) PHF-1, or (C) AT180 phosphoepitopes, and (D) total tau.
Relative immunoreactive band intensities are expressed as a percent of
control from a total Tau ratio and are displayed for each phosphoe-
pitope and total tau. For each condition, 2 representative data are
displayed with control (n =9) and 0.1% DMSO (n =9). Data are
expressed as mean 6 SD. *, ** denote p,0.05 and p,0.01, versus
control, respectively; Student’s t test.
doi:10.1371/journal.pone.0040020.g007
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CA). Immunolabeled tissues were observed under a Carl Zeiss
Axio Imager M2 microscope equipped with AxioCam MRm (Carl
Zeiss, Jena, Germany) and a Nuance FX multispectral imaging
system (Cambridge Research & Instrumentation, CRi, Woburn,
MA) and a Nuance 2.10 software.
Statistical Analysis
Group comparisons of immunoblot relative band intensities
were performed using a one-way analysis of variance (ANOVA)
with Newman-Keuls Multiple Comparison post hoc test applied
when appropriate or by means of an unpaired t-test. Statistical
calculations were performed using Prism 5 software (GraphPad
Software, Inc., San Diego, CA) and JMP 8 (SAS Institute, Cary,
NC), and all data are reported as mean 6 SD or SEM, with a
value of p,0.05 considered statistically significant.
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